Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ana Barat

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Oncotarget|May 11, 2017
Apelin: A putative novel predictive biomarker for bevacizumab response in colorectal cancerLinda Zuurbier, Arman Rahman, Martijn Cordes, et al.
Scientific Reports|June 20, 2020
Combination of variations in inflammation- and endoplasmic reticulum-associated genes as putative biomarker for bevacizumab response in KRAS wild-type colorectal cancerAna Barat, Dominiek Smeets, Bruce Moran, et al.
Nature Communications|October 7, 2018
Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapyDominiek Smeets, Ian S Miller, Darran P O'Connor, et al.
Scientific Reports|April 13, 2026
A pipeline of machine learning-driven multi-modal data fusion methods for prognostic risk analysis in bevacizumab-treated metastatic colorectal cancerValentina Thomas, Gift Nyamundanda, Adrian Lärkeryd, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Oncotarget|May 11, 2017
Apelin: A putative novel predictive biomarker for bevacizumab response in colorectal cancerLinda Zuurbier, Arman Rahman, Martijn Cordes, et al.
Scientific Reports|June 20, 2020
Combination of variations in inflammation- and endoplasmic reticulum-associated genes as putative biomarker for bevacizumab response in KRAS wild-type colorectal cancerAna Barat, Dominiek Smeets, Bruce Moran, et al.
Nature Communications|October 7, 2018
Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapyDominiek Smeets, Ian S Miller, Darran P O'Connor, et al.
Scientific Reports|April 13, 2026
A pipeline of machine learning-driven multi-modal data fusion methods for prognostic risk analysis in bevacizumab-treated metastatic colorectal cancerValentina Thomas, Gift Nyamundanda, Adrian Lärkeryd, et al.
Pageof 3